Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
At a glance
Conditions
NCT02977468
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Columbia University Irving Medical Center
New York, New Yorkstudy coordinator listed
Recruiting
Emory University
Atlanta, Georgiano site contact published
Recruiting
Loyola University Chicago
Maywood, Illinoisno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Eileen Connolly, MD · PRINCIPAL_INVESTIGATOR · Assistant Professor Of Radiation Oncology
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of subjects with significant mean percent change in TILs3 months
This outcome measure is designed to determine if immune modulation therapy with MK-3475 will increase TILs in newly diagnosed TNBC tumors. The mean percent change in TILS in tumor tissue from initial core biopsy samples will be compared with pathology samples from definitive surgery after two cycles of MK-3475.